The Amyotrophic Lateral Sclerosis Treatment Market is being driven by Increase in incidence and prevalence of amyotrophic lateral sclerosis
The Amyotrophic Lateral Sclerosis Treatment Market is expected to grow at a CAGR of 12.79% during 2023 and 2028. During this period, the market is also expected to show a growth of USD 663.7 million. The global aging population is experiencing significant growth due to declining fertility rates and increased longevity. This demographic shift has led to an increased prevalence of neurological disorders, including Amyotrophic Lateral Sclerosis (ALS). According to the World Health Organization (WHO), the proportion of the world's population aged 60 years and above is projected to nearly double from 12% to 22% between 2015 and 2050. In Sub-Saharan Africa, neurological disorders, particularly degenerative diseases such as dementia and Parkinson's disease, are common among the elderly. Consequently, the rising elderly population will fuel the expansion of the global ALS treatment market during the forecast period.
Get more information on Amyotrophic Lateral Sclerosis Treatment Market by requesting a sample report
The market is segmented based on
According to Technavio, There are several factors that are causing the market to flourish during the forecast period, which are as follows:
However, the market also witnesses some limitations, which are as follows:
Rich Experience: 20+ years leading global market research, trusted insights across industries.
Unlock Business Potential with Technavio: Maximize ROI with Technavio's tailored market research: deep dives and actionable insights.
Your Guide to Market Success: Empower your business with Technavio's market research and future-proof your decisions.
|
Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
157 |
|
Base year |
2023 |
|
Historic period |
2018-2022 |
|
Forecast period |
2024-2028 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 12.79% |
|
Market growth 2024-2028 |
USD 663.7 million |
|
Market structure |
fragmentation |
|
YoY growth 2023-2024(%) |
12.48 |
|
Key countries |
US, Canada, Germany, UK, Italy, France, China, India, Japan, Brazil, Egypt, UAE, Oman, Argentina, KSA, UAE, Brazil, Rest of World (ROW), US, Canada, Germany, UK, and China |
|
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
Find out which segment is leading the market by accessing the free PDF report
Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig's disease, is a neurodegenerative disorder affecting nerve cells in the central nervous system responsible for controlling voluntary muscles. Its causes include genetic inheritance and sporadic gene mutations. The disease leads to motor neuron degeneration, resulting in respiratory failure. Hospital pharmacies, retail pharmacies, and online providers distribute drug therapies to manage symptoms in the geriatric population, with a growing awareness and increasing incidence rate. The stationary lifestyle of patients and high treatment costs are challenges. Infection rates are a significant concern due to weakened immune systems.
The Amyotrophic Lateral Sclerosis (ALS) treatment market is a significant segment within the global pharmaceuticals industry, which encompasses entities involved in the research and development (R&D) or manufacturing of various pharmaceutical products, including both generic and non-generic drugs, as well as veterinary drugs. According to Technavio, the global healthcare market, which includes the pharmaceuticals sector, is projected to expand due to several key factors, such as the increasing aging population. With the global population aging, the number of individuals above 60 years is predicted to surge substantially, leading to a higher demand for healthcare products and services, including pharmaceuticals for conditions like ALS, which is characterized by the degeneration of nerve cells leading to motor neuron disease and often involves genetic inheritance and gene mutation.. Industries are leveraging the products belonging to the market for customer engagement, transactional notifications, and promotional offers.
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/
Safe and Secure SSL Encrypted
One user only.
Quick & easy download option
Unlimited user access (Within your organization).
Complimentary Customization Included
*For Enterprise license, go to checkout page
Get the report (PDF) sent to your email within minutes.
